Research Ethics Committee Reference Number	IRAS number	Full Name of Trial	Target number of patients available?	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Target date to recruit patients agreed?	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Date trial closed to recruitment	Reason for the closure of the trial
11/LO/0537	75448	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis	Number agreed	6	6	Date agreed	01/02/2013	5	24/11/2015	Recruitment finished
12/SW/0378	107545	Effect of Bivalirudin on Aortic Valve Intervention outcomes 2/3	Number agreed	20	20	Date agreed	01/04/2015	16	07/04/2015	Recruitment finished
13/NW/0316	124757	Phase 4 trial comparing cumulative incidence of SCC after treatment + ingenol mebutate & imiquimod for multiple actinic keratoses on face &scalp. A multi-centre, randomised, two-arm, open label, active-controlled, parallel group, 36-month trial.	Number agreed	8	8	Date agreed	31/05/2015	10	31/03/2016	Recruitment finished
13/YH/0282	133239	ACT-MOVE: ML28641 - Subcutaneous tocilizumab in rheumatoid arthritis	Range agreed	3	5	Date agreed	30/06/2015	3	27/04/2015	Recruitment finished
13/EE/0126	129195	Evaluation of Safety and Efficacy of the BACE™ [Basal Annuloplasty of the Cardia Externally] Device in the Treatment of Functional Mitral Valve Regurgitation [FMR]	Range agreed	6	10	Date agreed	01/07/2016	0	01/06/2015	Recruitment finished
14/LO/0081	144232	A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficicacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus	Number agreed	3	3	Date agreed	31/07/2015	2	01/07/2015	Recruitment finished
13/LO/1081	132715	PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer	Number agreed	4	4	Date agreed	01/02/2016	0	28/04/2015 (C	Recruitment finished
13/NE/0126	123725	An exploratory, randomised, double-blind, controlled study to assess the effect of an Amino Acid Based Formula with a synbiotic blend on gut microbiota and stool characteristics in infants with suspected gastrointestinal Non IgE mediated cow's milk allergy (CMA).	Number agreed	5	5	Date agreed	28/07/2014	7	Apr-15	Recruitment finished
14/LO/1381	153109	Reformulated raltegravir q.d. (1200 mg) versus raltegravir b.i.d. (400 mg) in ART-naïve pts	Number agreed	5	5	Date agreed	30/04/2015	5	05/12/2015	Withdrawn by Sponsor
14/LO/1513	158109	A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF or Efavirenz /Emtricitabine/Tenofovir DF) compared to Ritonavir boosted Atazanavir plus Abacavir/Lamivudine in Antiretroviral Treatment-naïve HIV-1 Infected Adults with eGFR ≥70 mL/min	Number agreed	3	3	Date agreed	31/12/2015	3	21/05/2015	Recruitment finished
14/LO/0298	148388	A multicenter, Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate.	Range agreed	10	15	Date agreed	01/08/2016	5	21/4/15 (CW)	Recruitment finished
14/YH/0086	147377	RESPOND: Repositionable Lotus Valve System-Post Market Evaluation of Real World Clincial Outcomes	Range agreed	15	30	Date agreed	31/12/2015	111	01/02/2016	Recruitment finished
13/YH/0147	131219	A Randomized, Open Label, Multi-Centre, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects with Acute Alcoholic Hepatitis (AAH) Who Have Failed Steroid Therapy (incorporating VTI-210E as a follow-up registry)	Range agreed	4	6	Date agreed	31/08/2015	0	21/08/2015	Recruitment finished
14/EM/1070	159169	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults	Number agreed	1	1	Date agreed	01/10/2015	1	20/08/2015	Recruitment finished
14/LO/1435	157357	A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus EnbrelÃ® in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate	Number agreed	3	3	Date agreed	30/05/2016	0	07/04/2015	Recruitment finished
13/YH/0315	133181	A randomized, parallel group, open-label, multicentre study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anemia in pre-dialysis subjects with chronic kidney disease on and Asia Pacificdarbepoetin treatment in Europe	Range agreed	1	2	Date agreed	31/03/2015	0	10/06/2015	Recruitment finished
14/SS/1048	154401	A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/day, Split-dose) in Subjects with Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease	Range agreed	5	7	Date agreed	10/07/2015	2	01/03/2016	Recruitment finished
13/NI/0188	140146	A single-arm trial to evaluate the effectiveness of PCI of de novo 3-vessel disease applying the SYNTAX Score II with pressure wire functional assessment and IVUS guidance, using an everolimus-eluting stent with biodegradable abluminal coating	Range agreed	10	40	Date agreed	01/03/2016	6	08/09/2015	Recruitment finished
14/WM/1210	164208	A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed, human immunodeficiency disoproxil fumarate (FTC/TDF) in virologically-suppressed, human immunodeficiency virus type 1 (HIV-1) infected subjects.	Number agreed	4	4	Date agreed	12/08/2015	11	29/01/2016	Recruitment finished
15/LO/0075	164748	A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects	Number agreed	5	5	Date agreed	01/03/2018	3	27/08/2015	Withdrawn by Sponsor
14/NE/1185	152820	Short duration of dual antiplatElet therapy with SyNergy® II everolimus eluting stent in patients Older than 75 years undergoing percutaneous coronary Revascularization. The SENIOR trial	Range agreed	15	40	Date agreed	30/06/2015	7	11/02/2016	Recruitment finished